标题
Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
作者
关键词
-
出版物
Cancers
Volume 14, Issue 6, Pages 1550
出版商
MDPI AG
发表日期
2022-03-21
DOI
10.3390/cancers14061550
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.
- (2021) Guillaume Joe Pegna et al. JOURNAL OF CLINICAL ONCOLOGY
- Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells
- (2021) Fumihiko Matsuzawa et al. BMC CANCER
- Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model
- (2021) Yanan Wang et al. Frontiers in Immunology
- Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
- (2021) Laura Castelletti et al. Biomarker Research
- Furin is not required for processing of mesothelin precursor protein
- (2021) Sarah Joseph et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model
- (2021) Yuki Fujii et al. INVESTIGATIONAL NEW DRUGS
- Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues
- (2021) Frans V Suurs et al. JOURNAL OF NUCLEAR MEDICINE
- Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
- (2021) Sören Weidemann et al. Biomedicines
- Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia
- (2021) Allison J. Kaeding et al. Blood Advances
- Mesothelin Expression is Correlated with Chemoresistance in Stage IV Colorectal Cancer
- (2021) Ken Nagata et al. ANNALS OF SURGICAL ONCOLOGY
- Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness
- (2021) Sören Weidemann et al. CANCER INVESTIGATION
- Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
- (2021) Zhenguang Wang et al. Cellular & Molecular Immunology
- Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
- (2021) Quy Le et al. CLINICAL CANCER RESEARCH
- Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor Natural Killer Cell Therapy in Acute Myeloid Leukemia
- (2021) Thao T. Tang et al. BLOOD
- Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
- (2021) Sylvie Rottey et al. CLINICAL CANCER RESEARCH
- Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo
- (2021) Guodi Liu et al. EXPERIMENTAL CELL RESEARCH
- Host Mesothelin Expression Increases Ovarian Cancer Metastasis in the Peritoneal Microenvironment
- (2021) Tyvette S. Hilliard et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells
- (2021) Leila Jafarzadeh et al. MOLECULAR IMMUNOLOGY
- Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies
- (2021) Anilkumar Gopalakrishnapillai et al. Cancers
- TIM-3 in Leukemia; Immune Response and Beyond
- (2021) Mahnaz Rezaei et al. Frontiers in Oncology
- Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score
- (2021) Federica Grosso et al. Diagnostics
- Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer
- (2020) Bihui Cao et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
- (2020) Aerin Yoon et al. Biomolecules
- Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer
- (2020) Takahiro Tsujikawa et al. CLINICAL CANCER RESEARCH
- First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
- (2020) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
- (2020) Chuan Tong et al. BLOOD
- From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma
- (2020) Christopher Montemagno et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models
- (2020) Qun Jiang et al. Science Translational Medicine
- Histoepigenetic analysis of the mesothelin network within pancreatic ductal adenocarcinoma cells reveals regulation of retinoic acid receptor gamma and AKT by mesothelin
- (2020) Eugene Lurie et al. Oncogenesis
- Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
- (2020) Brendan L. Hagerty et al. Biomolecules
- Phase 1 study of the immunotoxin LMB‐100 in patients with mesothelioma and other solid tumors expressing mesothelin
- (2020) Raffit Hassan et al. CANCER
- Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors
- (2020) Mary Ellen Molloy et al. CLINICAL CANCER RESEARCH
- PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells
- (2020) Guodi Liu et al. HUMAN IMMUNOLOGY
- Multiple proteases are involved in mesothelin shedding by cancer cells
- (2020) Xiufen Liu et al. Communications Biology
- Synergistic Effect of a Mesothelin Targeted Thorium-227 Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
- (2019) Katrine Wickstroem et al. JOURNAL OF NUCLEAR MEDICINE
- The basics of epithelial–mesenchymal transition (EMT): A study from a structure, dynamics, and functional perspective
- (2019) Vishal Das et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study)
- (2019) Dung T. Le et al. CLINICAL CANCER RESEARCH
- Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers
- (2019) Urs B Hagemann et al. CLINICAL CANCER RESEARCH
- Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma
- (2019) Raffit Hassan et al. CLINICAL CANCER RESEARCH
- Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers
- (2019) Andrew R. Haas et al. MOLECULAR THERAPY
- A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
- (2019) Joanie Del Bano et al. Frontiers in Immunology
- In Vivo Evaluation of Mesothelin As a Therapeutic Target in Pediatric Acute Myeloid Leukemia
- (2019) Anilkumar Gopalakrishnapillai et al. BLOOD
- Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
- (2019) Xiao Han et al. Journal of Hematology & Oncology
- Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma
- (2019) Christine Alewine et al. CLINICAL CANCER RESEARCH
- Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer
- (2018) Jian-Feng Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
- (2018) Maria Quanz et al. Oncotarget
- The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
- (2018) Tyvette Hilliard Cancers
- Mesothelin‑targeted second generation CAR‑T cells inhibit growth of mesothelin‑expressing tumors in�vivo
- (2018) Lin Ye et al. Experimental and Therapeutic Medicine
- Targeted Alpha Therapy, an Emerging Class of Cancer Agents
- (2018) et al. JAMA Oncology
- Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells
- (2017) Xiaoqing He et al. Molecular Cancer
- Identification of MiR-21-5p as a Functional Regulator of Mesothelin Expression Using MicroRNA Capture Affinity Coupled with Next Generation Sequencing
- (2017) Chiara De Santi et al. PLoS One
- Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
- (2016) Mark O'Hara et al. Immunotherapy
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
- (2016) Raffit Hassan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
- (2016) C. D. Weekes et al. MOLECULAR CANCER THERAPEUTICS
- ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment
- (2015) L. E. Lamberts et al. CLINICAL CANCER RESEARCH
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
- (2015) A. Morello et al. Cancer Discovery
- Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
- (2015) Kevin Hollevoet et al. PLoS One
- Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
- (2014) I. Pastan et al. CANCER RESEARCH
- Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
- (2014) R. Hassan et al. CLINICAL CANCER RESEARCH
- Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
- (2014) S. Golfier et al. MOLECULAR CANCER THERAPEUTICS
- In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer
- (2014) K. Hollevoet et al. MOLECULAR CANCER THERAPEUTICS
- Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
- (2014) Jingli Zhang et al. PLoS One
- The Role of Mesothelin in Tumor Progression and Targeted Therapy
- (2013) Zhewei Tang et al. Anti-Cancer Agents in Medicinal Chemistry
- A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer
- (2013) C. Marin-Muller et al. CLINICAL CANCER RESEARCH
- Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
- (2013) R. Hassan et al. Science Translational Medicine
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation
- (2013) Shih-Hsun Chen et al. Scientific Reports
- Recognition of Mesothelin by the Therapeutic Antibody MORAb-009
- (2012) Jichun Ma et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development
- (2012) R. J. Kelly et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells
- (2012) Kun Wang et al. PLoS One
- Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma
- (2012) Liping Yu et al. Journal of Cancer
- Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways
- (2011) Ming-Cheng Chang et al. BIOCHEMICAL JOURNAL
- Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation
- (2011) U. Bharadwaj et al. CARCINOGENESIS
- A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
- (2011) D. T. Le et al. CLINICAL CANCER RESEARCH
- Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
- (2011) Evripidis Lanitis et al. MOLECULAR THERAPY
- Mannose Receptor (MR) Engagement by Mesothelin GPI Anchor Polarizes Tumor-Associated Macrophages and Is Blocked by Anti-MR Human Recombinant Antibody
- (2011) Denarda Dangaj et al. PLoS One
- Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers
- (2010) R. Hassan et al. CLINICAL CANCER RESEARCH
- Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter
- (2010) Ke Tan et al. HUMAN PATHOLOGY
- Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats
- (2009) Bangalore K Sathyanarayana et al. BMC STRUCTURAL BIOLOGY
- The Glycosylphosphatidylinositol Anchor: A Complex Membrane-Anchoring Structure for Proteins†
- (2008) Margot G. Paulick et al. BIOCHEMISTRY
- A Binding Domain on Mesothelin for CA125/MUC16
- (2008) Osamu Kaneko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mesothelin-Induced Pancreatic Cancer Cell Proliferation Involves Alteration of Cyclin E via Activation of Signal Transducer and Activator of Transcription Protein 3
- (2008) U. Bharadwaj et al. MOLECULAR CANCER RESEARCH
- Mesothelin Promotes Anchorage-Independent Growth and Prevents Anoikis via Extracellular Signal-Regulated Kinase Signaling Pathway in Human Breast Cancer Cells
- (2008) N. Uehara et al. MOLECULAR CANCER RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started